Current HealthCare CEO Arthur J. Higgins will leave the company as planned on April 30, 2010 at his own request. “Over the past years, Arthur Higgins has made a decisive contribution to the restructuring and strengthening of Bayer HealthCare and has set new trends,” said Wenning. “We thank him for his great commitment and wish him well for the future.” Dr. Marijn Dekkers, member of the Bayer AG Board of Management and its designated Chairman, will additionally take over as head of Bayer HealthCare on a temporary basis as planned from May 1, 2010 until Dr. Reinhardt’s appointment takes effect.
Dr. Jörg Reinhardt, born on March 11, 1956 in Homburg in the German state of Saarland, studied pharmaceutical sciences at the University of Saarbrücken. After obtaining his doctorate in 1981, he started his career with Sandoz, a predecessor company of Novartis, in 1982, holding various managerial positions of increasing responsibility in research and development. He was appointed Head of Corporate Development in 1994. After the formation of Novartis in 1996, he served as Head of Preclinical Development and Project Management before being appointed Global Head of Development in 1999. In this capacity he was responsible for clinical, pharmaceutical, chemical and biotechnological development, drug safety testing and regulatory affairs. At the end of 2005 he was appointed CEO of the Vaccines & Diagnostics Division, San Francisco/Boston, United States. At the end of 2008, Reinhardt returned to Switzerland to become Chief Operating Officer (COO) of Novartis, a position he held until the end of January 2010. In this capacity Reinhardt was responsible for all four of the group’s divisions as well as for Human Resources, IT, Corporate Affairs and Communications. He was also a member of the company’s Executive Committee.
From 2000 until January 2010, Reinhardt also served as Chairman of the Board of Directors of the Genomics Institute of the Novartis Foundation in La Jolla, California. From 2001 through 2004 he was a member of the Supervisory Board of MorphoSys AG, Germany, which specializes in researching and developing monoclonal antibodies.
Arthur J. Higgins
Arthur J. Higgins was born on March 6, 1956 in Airdrie, Scotland. He studied at Scotland's Strathclyde University from 1974 to 1978, where he gained a Bachelor of Science in biochemistry. He began his career in 1978 with Bristol-Myers in the U.K. After working for Sandoz (1979 to 1984) and Fisons (1984 to 1987), Higgins moved to Abbott Laboratories in the United States (1987 to 2001), where he held positions of increasing responsibility in the international and domestic divisions. In 2001, he was appointed Chairman and CEO of Enzon Pharmaceuticals, headquartered in Bridgewater, New Jersey. Arthur Higgins has headed up Bayer HealthCare since July 1, 2004. During his tenure, the business of pharmaceuticals company Schering AG, Berlin, Germany, and the over-the-counter medicines business of Roche were integrated into Bayer HealthCare.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. The company’s products and services are designed to benefit people and improve their quality of life. At the same time Bayer creates value through innovation, growth and improved earning power. The Group is committed to the principles of sustainable development and to its role as a socially and ethically responsible corporate citizen. Economy, ecology and social commitment are corporate policy objectives of equal rank. In 2009, Bayer employed some 108,400 people and had sales of EUR 31.2 billion. Capital expenditures amounted to EUR 1.7 billion, R&D expenses to EUR 2.7 billion.
About Bayer HealthCare
Bayer HealthCare, a subgroup of Bayer AG, is one of the world’s leading innovative companies in the health care and medical products industry. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.